A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders

Am J Psychiatry. 2017 Jul 1;174(7):695-696. doi: 10.1176/appi.ajp.2017.17020239.

Authors

Samuel T Wilkinson¹, Mesut Toprak¹, Mason S Turner¹, Steven P Levine¹, Rachel B Katz¹, Gerard Sanacora¹

Affiliation

¹ From the Department of Psychiatry, Yale School of Medicine, New Haven, Conn.; Kaiser Permanente Northern California, San Francisco; and Ketamine Treatment Centers, Princeton, N.J.

No abstract available

Keywords: Epidemiology; Ketamine; Mood Disorders-Bipolar; Mood Disorders-Unipolar.

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antidepressive Agents / therapeutic use*
Antimanic Agents / therapeutic use*
Bipolar Disorder / drug therapy*
Depressive Disorder / drug therapy*
Health Care Surveys
Humans
Ketamine / therapeutic use*
Off-Label Use
Stress Disorders, Post-Traumatic / drug therapy*
Treatment Outcome

Substances

Antidepressive Agents
Antimanic Agents
Ketamine

Grants and funding